Evaluation of Pharmacokinetic Compatibility of XueBiJing Injection with Antibiotics Co‐administered in Management of Sepsis

Abstract

Sepsis is life‐threatening organ dysfunction caused by a dysregulated host response to infection. XueBiJing, an intravenous injection approved by the China FDA in 2004, has been incorporated into conventional sepsis management, which relies on timely and appropriate antibiotics and resuscitation therapies. In China, about 800,000 patients use XueBiJing injection each year and 80% of them are patients with sepsis or septic shock. The injection is prepared from a combination of Carthamus tinctorius flowers (Honghua in Chinese), Paeonia lactiflora roots (Chishao), Ligusticum chuanxiong rhizomes (Chuanxiong), Angelica sinensis roots (Danggui), and Salvia miltiorrhiza roots (Danshen). Many clinical studies in China suggested that adding XueBiJing injection to conventional management of sepsis reduces patients' 28‐day mortality and incidence of complications, improves their Acute Physiology and Chronic Health Evaluation II scores and prognosis, and shortens their stay in intensive care units, with low incidence of side effects. Despite the promising results of clinical studies, success of such combination drug therapies containing XueBiJing injection also relies on PK compatibility, i.e., exhibiting limited pharmacokinetic interaction problems that can counteract the drugs' synergistic or additive pharmacodynamic effects, as well as their safety. In this presentation, the speaker will report evaluation, by his lab, of pharmacokinetic compatibility of XueBiJing injection with antibiotics co‐administered in management of sepsis.This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.